Menu Search
Equities

ACADIA Pharmaceuticals Inc

DR6:BER

ACADIA Pharmaceuticals Inc

Actions
  • Price (EUR)14.59
  • Today's Change-0.06 / -0.41%
  • Shares traded80.00
  • 1 Year change-35.46%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ACADIA Pharmaceuticals Inc grew revenues 40.45% from 517.24m to 726.44m while net income improved from a loss of 215.98m to a smaller loss of 61.29m.
Gross margin91.72%
Net profit margin3.43%
Operating margin2.56%
Return on assets3.93%
Return on equity6.70%
Return on investment5.93%
More ▼

Cash flow in USDView more

In 2023, ACADIA Pharmaceuticals Inc increased its cash reserves by 61.20%, or 73.81m. Cash Flow from Investing totalled 32.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 16.70m in cash from operations while cash generated from financing totalled 25.13m.
Cash flow per share0.2540
Price/Cash flow per share64.81
Book value per share3.12
Tangible book value per share2.47
More ▼

Balance sheet in USDView more

ACADIA Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio2.16
Quick ratio1.95
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.